127 related articles for article (PubMed ID: 24200836)
1. Identification of plasma complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach.
Kim PY; Tan O; Diakiw SM; Carter D; Sekerye EO; Wasinger VC; Liu T; Kavallaris M; Norris MD; Haber M; Chesler L; Dolnikov A; Trahair TN; Cheung NK; Marshall GM; Cheung BB
J Proteomics; 2014 Jan; 96():1-12. PubMed ID: 24200836
[TBL] [Abstract][Full Text] [Related]
2. miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs.
Terrile M; Bryan K; Vaughan L; Hallsworth A; Webber H; Chesler L; Stallings RL
PLoS One; 2011; 6(12):e28356. PubMed ID: 22164278
[TBL] [Abstract][Full Text] [Related]
3. Quantitative proteomic analysis of human plasma using tandem mass tags to identify novel biomarkers for herpes zoster.
Wang T; Shen H; Deng H; Pan H; He Q; Ni H; Tao J; Liu S; Xu L; Yao M
J Proteomics; 2020 Aug; 225():103879. PubMed ID: 32585426
[TBL] [Abstract][Full Text] [Related]
4. A simple PCR method for rapid genotype analysis of the TH-MYCN transgenic mouse.
Haraguchi S; Nakagawara A
PLoS One; 2009 Sep; 4(9):e6902. PubMed ID: 19730731
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma.
Jamin Y; Tucker ER; Poon E; Popov S; Vaughan L; Boult JK; Webber H; Hallsworth A; Baker LC; Jones C; Koh DM; Pearson AD; Chesler L; Robinson SP
Radiology; 2013 Jan; 266(1):130-40. PubMed ID: 23169794
[TBL] [Abstract][Full Text] [Related]
6. Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma.
Rasmuson A; Segerström L; Nethander M; Finnman J; Elfman LH; Javanmardi N; Nilsson S; Johnsen JI; Martinsson T; Kogner P
PLoS One; 2012; 7(12):e51297. PubMed ID: 23284678
[TBL] [Abstract][Full Text] [Related]
7. Detection of MYCN amplification using blood plasma: noninvasive therapy evaluation and prediction of prognosis in neuroblastoma.
Kojima M; Hiyama E; Fukuba I; Yamaoka E; Ueda Y; Onitake Y; Kurihara S; Sueda T
Pediatr Surg Int; 2013 Nov; 29(11):1139-45. PubMed ID: 24022278
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.
Chen L; Esfandiari A; Reaves W; Vu A; Hogarty MD; Lunec J; Tweddle DA
Int J Oncol; 2018 Mar; 52(3):967-977. PubMed ID: 29393340
[TBL] [Abstract][Full Text] [Related]
9. Molecular imaging of neuroblastoma progression in TH-MYCN transgenic mice.
Quarta C; Cantelli E; Nanni C; Ambrosini V; D'ambrosio D; Di Leo K; Angelucci S; Zagni F; Lodi F; Marengo M; Weiss WA; Pession A; Tonelli R; Fanti S
Mol Imaging Biol; 2013 Apr; 15(2):194-202. PubMed ID: 22777578
[TBL] [Abstract][Full Text] [Related]
10. Proteomic biomarkers for psoriasis and psoriasis arthritis.
Reindl J; Pesek J; Krüger T; Wendler S; Nemitz S; Muckova P; Büchler R; Opitz S; Krieg N; Norgauer J; Rhode H
J Proteomics; 2016 May; 140():55-61. PubMed ID: 27063990
[TBL] [Abstract][Full Text] [Related]
11. An unexpected role for caspase-2 in neuroblastoma.
Dorstyn L; Puccini J; Nikolic A; Shalini S; Wilson CH; Norris MD; Haber M; Kumar S
Cell Death Dis; 2014 Aug; 5(8):e1383. PubMed ID: 25144718
[TBL] [Abstract][Full Text] [Related]
12. Histological profile of tumours from MYCN transgenic mice.
Moore HC; Wood KM; Jackson MS; Lastowska MA; Hall D; Imrie H; Redfern CP; Lovat PE; Ponthan F; O'Toole K; Lunec J; Tweddle DA
J Clin Pathol; 2008 Oct; 61(10):1098-103. PubMed ID: 18682419
[TBL] [Abstract][Full Text] [Related]
13. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.
Kroesen M; Nierkens S; Ansems M; Wassink M; Orentas RJ; Boon L; den Brok MH; Hoogerbrugge PM; Adema GJ
Int J Cancer; 2014 Mar; 134(6):1335-45. PubMed ID: 24038106
[TBL] [Abstract][Full Text] [Related]
14. Tumor-homing effect of human mesenchymal stem cells in a TH-MYCN mouse model of neuroblastoma.
Kimura K; Kishida T; Wakao J; Tanaka T; Higashi M; Fumino S; Aoi S; Furukawa T; Mazda O; Tajiri T
J Pediatr Surg; 2016 Dec; 51(12):2068-2073. PubMed ID: 27686479
[TBL] [Abstract][Full Text] [Related]
15. Butyrylcholinesterase as a Blood Biomarker in Neuroblastoma.
Coulter DW; Boettner AD; Kortylewicz ZP; Enke SP; Luther JA; Verma V; Baranowska-Kortylewicz J
J Pediatr Hematol Oncol; 2017 May; 39(4):272-281. PubMed ID: 28375942
[TBL] [Abstract][Full Text] [Related]
16. Novel mesenchymal stem cell delivery system as targeted therapy against neuroblastoma using the TH-MYCN mouse model.
Maniwa J; Fumino S; Kimura K; Tanaka T; Higashi M; Kishida T; Mazda O; Tajiri T
J Pediatr Surg; 2019 Dec; 54(12):2600-2605. PubMed ID: 31627888
[TBL] [Abstract][Full Text] [Related]
17. Natural antibody against neuroblastoma of TH-MYCN transgenic mice does not correlate with spontaneous regression.
Kawakubo N; Harada Y; Ishii M; Souzaki R; Kinoshita Y; Tajiri T; Taguchi T; Yonemitsu Y
Biochem Biophys Res Commun; 2018 Sep; 503(3):1666-1673. PubMed ID: 30054041
[TBL] [Abstract][Full Text] [Related]
18. Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma.
Yagyu S; Iehara T; Tanaka S; Gotoh T; Misawa-Furihata A; Sugimoto T; London WB; Hogarty MD; Teramukai S; Nakagawara A; Hiyama E; Maris JM; Hosoi H
PLoS One; 2016; 11(8):e0161039. PubMed ID: 27513929
[TBL] [Abstract][Full Text] [Related]
19. Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis.
Carter DR; Sutton SK; Pajic M; Murray J; Sekyere EO; Fletcher J; Beckers A; De Preter K; Speleman F; George RE; Haber M; Norris MD; Cheung BB; Marshall GM
Mol Oncol; 2016 Jun; 10(6):866-78. PubMed ID: 26996379
[TBL] [Abstract][Full Text] [Related]
20. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
